Contemporary evaluation of acute myeloid leukemia patients with long‐term survival exceeding 5years

ObjectivesDefine clinical and laboratory attributes of acute myeloid leukemia (AML) patients with long‐term survival exceeding five years and compare them with AML patients succumbing to disease within 2 years of diagnosis.MethodsA retrospective analysis of AML patients alive at least five years from the time of initial diagnosis. Baseline clinical data were compared with patients who died within 2 years of diagnosis.ResultsThe long‐term cohort consisted of 93 patients treated in 2007–2016 with a median follow‐up duration of 7.7 years (range 5–13.6 years). European LeukemiaNet (ELN) 2017 favorable risk patients accounted for 60% of the cohort. All long‐term survivors achieved remission following induction chemotherapy. Multivariate analysis showed that compared with 132 patients experiencing death within 2 years of diagnosis, long‐term survivors were more likely to be of younger age [odds ratio (OR), 0.92; 95% confidence interval (CI), 0.9–0.95; p